Long‐term outcomes of anti‐thyroid drug treatment in childhood‐onset Graves' disease
Authors' conclusion
Remission rate of childhood-onset GD was relatively low following ATD treatment. Longer-term ATD therapy was associated with increased remission rate. Approximately 50% of patients with relapse had disease relapse within 1 year following ATD discontinuation.
Study context
- Population
- Paediatric patients with childhood-onset Graves' disease (GD) initially treated with anti-thyroid drug (ATD); median (IQR) age at diagnosis 11.5 (9.4, 13.7) years
- Participants
- 265 patients
- Outcome
- Long-term outcomes following ATD therapy, including remission and relapse rates
Main finding
As reported in the abstract
median 7.1 (3.8, 10.9) years since diagnosis
Remission rate
21%
56 out of 265 patients
Relapse rate
40%
37 out of 93 patients
Observational data: associations, not effects.
Further findings
Outcome status
- Underwent definitive treatment
- 77
- Had ATD discontinuation
- 93
- Still treated with ATD
- 95
- Duration of ATD treatment, median (IQR), years
- 4.3 (2.3, 6.7)
Cumulative incidence of first remission
- Increased with duration of ATD treatment; maximum remission rate at (years after ATD therapy)
- 5.3
Timing of relapse
- Among relapsed patients, relapse within 1 year after ATD discontinuation
- ≈50%
Predictors of remission
- More likely remission with goitre <3.5 cm, TRAb <10 IU/L, no ophthalmopathy at diagnosis and MMI dose <0.25 mg/kg/day at 1 year
Original publication
Long‐term outcomes of anti‐thyroid drug treatment in childhood‐onset Graves' disease. Clin Endocrinol (Oxf). Published 31 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →